NASH treatment ASO(UGISense)

N/A

Report date: 2025/09/05 17:15:20
NME

Base Information

Drug NameNASH treatment ASO(UGISense)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUGISense AG
China Registration ClassN/A

Develop Information

Active CompaniesUGISense AG
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A